Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05433441
Recruiting Not applicable

Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

NCT05433441 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-12-06
Last updated
2025-07-23

Condition(s) studied

Parkinson Disease

Investigational drug(s) / intervention(s)

ESPark Intervention

ESPark Intervention: The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.

Study summary

A pilot experiment interventional study is proposed in order to set up multidisciplinary team for Parkinson's patients at home. The aim of this study is to evaluate the effectiveness of this specialized Parkinson's team (ESPark) intervention a on the quality of life of patients with moderate to severe Parkinson's disease

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: For the patient: * Patient with a diagnosis of idiopathic Parkinson's disease * Patient over 18 years ; * Patient with a Hoehn and Yahr Stage greater than or equal to 3; * Patient without major cognitive impairment defined by a MOCA score ≥21 * Patient living at home ; * Patient with an identified non-professional primary caregiver; * Person affiliated with or benefiting from a social security plan; * Free, informed and and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research). For the caregiver: * Male or female over 18 years * Able to respond to research interviews/questionnaires * Free, informed and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research). Exclusion Criteria: For the patient: * Patient with medically indicated dementia impairing comprehension and adherence, and/or with severe confusion or psycho-hallucinatory state; * Institutionalized or foster care patients; * Patients with a known severe and unstable general pathology that does not allow for patient follow-up; * Patients already included in another non-drug management trial; * Patients whose institutionalization is envisaged in the short term (within 6 months) or for whom a change of residence is envisaged in the short term and would not allow for follow-up assessments; * Patients under guardianship or unable to express consent * Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up; * Presence of a primary caregiver with a known severe and unstable disease that does not allow for the conduct of the study; * Presence of a primary caregiver with a known cognitive or psychiatric disorder (chronic progressive psychosis) that does not allow for the proper conduct of the study. * Pregnant or breastfeeding woman. For the caregiver: * Unable to follow the research interviews or questionnaires. * Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up; * Primary caregiver with a known severe and unstable illness that does not allow for the proper conduct of the study; * Primary caregiver with known cognitive or psychiatric disorders (chronic progressive psychosis) that do not allow the study to be conducted properly.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Hopital Pellegrin Bordeaux France Recruiting
CHU de Lille Lille France Recruiting
CHU de Limoges Limoges France Recruiting
CHU Poitiers Poitiers France Recruiting

More University Hospital, Bordeaux trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05433441 on ClinicalTrials.gov ↗ ← All trials in France